Foster Nexthaler

Foster Nexthaler Special Precautions

Manufacturer:

OEP Phils

Distributor:

Zuellig
Full Prescribing Info
Special Precautions
It is recommended that the dose is tapered when the treatment is discontinued; treatment should not be stopped abruptly.
The management of asthma should normally follow a stepwise programme and patient response should be monitored clinically and by lung function tests.
If patients find the treatment ineffective medical attention must be sought. Increasing use of rescue bronchodilators indicates a worsening of the underlying condition and warrants a reassessment of the asthma therapy. Sudden and progressive deterioration in control of asthma is potentially life-threatening and the patient should undergo urgent medical assessment. Consideration should be given to the need for increased treatment with corticosteroids, either inhaled or oral therapy, or antibiotic treatment if an infection is suspected.
Patients should not be initiated on Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma. Serious asthma-related adverse events and exacerbations may occur during treatment with Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler). Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation on Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler).
As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing, cough and shortness of breath after dosing. This should be treated immediately with a fast-acting inhaled bronchodilator. Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) is not intended for the initial management of asthma.
For treatment of acute asthma attacks patients should be advised to have their short-acting bronchodilator available at all times, either Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) (for patients using Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) as maintenance and reliever therapy) or a separate rapid-acting bronchodilator (for patients using Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) as maintenance therapy only).
Patients should be reminded to take Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) daily as prescribed even when asymptomatic. The reliever inhalations of beclometasone dipropionate/formoterol fumarate dihydrate (Foster Nexthaler) should be taken in response to asthma symptoms, but are not intended for regular prophylactic use, e.g. before exercise. For such use, a separate rapid-acting bronchodilator should be considered.
Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler). Regular review of patients as treatment is stepped down is important. The lowest effective dose of Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) should be used (see Dosage & Administration).
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, glaucoma, and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is important therefore that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.
Prolonged treatment of patients with high doses of inhaled corticosteroids may result in adrenal suppression and acute adrenal crisis. Children and adolescents aged less than 16 years inhaling higher than recommended doses of beclometasone dipropionate may be at particular risk. Situations which could potentially trigger acute adrenal crisis, include trauma, surgery, infection or any rapid reduction in dosage. Presenting symptoms are typically vague and may include anorexia, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, hypotension, decreased level of consciousness, hypoglycaemia, and seizures. Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
Patients transferring from oral to inhaled corticosteroids may remain at risk of impaired adrenal reserve for a considerable time. Patients who have required high dose emergency corticosteroid therapy in the past or have received prolonged treatment with high doses of inhaled corticosteroids may also be at risk. This possibility of residual impairment should always be borne in mind in emergency and elective situations likely to produce stress, and appropriate corticosteroid treatment must be considered. The extent of the adrenal impairment may require specialist advice before elective procedures.
Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) should be administered with caution in patients with active or quiescent pulmonary tuberculosis, fungal and viral infections in the airways.
Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) should be used with caution (which may include monitoring) in patients with cardiac arrhythmias, especially third degree atrioventricular block and tachyarrhythmias, idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, ischaemic heart disease, severe heart failure, severe arterial hypertension and aneurysm.
Caution should also be observed when treating patients with known or suspected prolongation of the QTc interval, either congenital or drug induced (QTc >0.44 seconds). Formoterol itself may induce prolongation of the QTc interval.
Caution is also required when Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) is used by patients with thyrotoxicosis, diabetes mellitus, phaeochromocytoma and untreated hypokalaemia.
Potentially serious hypokalaemia may result from beta2-agonist therapy. Particular caution is advised in severe asthma as this effect may be potentiated by hypoxia. Hypokalaemia may also be potentiated by concomitant treatment with other drugs which can induce hypokalaemia, such as xanthine derivatives, steroids and diuretics (see Interactions). Caution is also recommended in unstable asthma when a number of "rescue" bronchodilators may be used. It is recommended that serum potassium levels are monitored in such situations.
The inhalation of formoterol may cause a rise in blood glucose levels. Therefore blood glucose should be closely monitored in patients with diabetes.
If anaesthesia with halogenated anaesthetics is planned, it should be ensured that Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) is not administered for at least 12 hours before the start of anaesthesia as there is a risk of cardiac arrhythmias.
Patients should be advised to rinse the mouth or gargle with water or brush the teeth after inhaling the prescribed dose to minimise the risk of oropharyngeal fungal infections and dysphonia.
Lactose contains small amounts of milk proteins, which may cause allergic reactions. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Visual disturbance: Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Effects on ability to drive and use machines: Beclometasone dipropionate/Formoterol fumarate dihydrate (Foster Nexthaler) has no or negligible influence on the ability to drive and use machines.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in